Search Results - "Lazarovici, J."

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper by Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., Ederhy, S., Feuillet, S., François, H., Lazarovici, J., Le Pavec, J., De Martin, E., Mateus, C., Michot, J.-M., Samuel, D., Soria, J.-C., Robert, C., Eggermont, A., Marabelle, A.

“…Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma…”
Get full text

Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? by Michot, J.M., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A.L., Ebbo, M., Godeau, B., Michel, M., Ribrag, V., Lambotte, O.

“…Immune checkpoint inhibitors (ICIs) are changing the treatments of many patients with cancer. These immunotherapies are generally better tolerated than…”
Get full text

EZH2 alterations in follicular lymphoma: biological and clinical correlations by Huet, S, Xerri, L, Tesson, B, Mareschal, S, Taix, S, Mescam-Mancini, L, Sohier, E, Carrère, M, Lazarovici, J, Casasnovas, O, Tonon, L, Boyault, S, Hayette, S, Haioun, C, Fabiani, B, Viari, A, Jardin, F, Salles, G

“…The histone methyltransferase EZH2 has an essential role in the development of follicular lymphoma (FL). Recurrent gain-of-function mutations in EZH2 have been…”
Get full text

Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases by Gueiderikh, A, Ung, M, Lazarovici, J, Danu, A, Ghez, D, Saleh, K, Dragani, M, Noël, N, Bigenwald, C, Willekens, C, Ribrag, V, Michot, J-M, Martin, V

“…Follicular lymphoma (FL) is one of the most common lymphoma. Occasionally, FL is associated with tumoral epidural compression and management of these patients…”
Get full text

EARLY FDG‐PET ADAPTED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA (HL): 10Y LONG TERM FOLLOW‐UP ANALYSIS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIAL by Federico, M., Fortpied, C., Stepanishyna, Y., Gotti, M., Maazen, R., Amorin, S., Re, A., Plattel, W., Lazarovici, J., Merli, F., Specht, L., Colella, J. S., Hutchings, M., Versari, A., Edeline, V., Stamatoulas, A., Girinsky, T., Ricardi, U., Aleman, B., Meulemans, B., Tonino, S., Raemaekers, J., André, M.

Get full text

MOLECULAR CHARACTERIZATION CONTRIBUTES TO DIAGNOSIS AND PREDICTS OUTCOME IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMAS: A LYSA STUDY by Camus, V., Viailly, P., Sesques, P., Drieux, F., Veresezan, E., Haioun, C., Durot, E., Patey, M., Rossi, C., Martin, L., Rainville, V., Bohers, E., Ruminy, P., Viennot, M., Paillassa, J., Tournilhac, O., Willaume, A., Antier, C., Lazarovici, J., Lévêque, E., Decazes, P., Becker, S., Tonnelet, D., Berriolo‐Riedinger, A., Gaulard, P., Tilly, H., Molina, T. J., Traverse‐Glehen, A., Jardin, F.

Get full text

Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study by Lazarovici, Julien, Dartigues, Peggy, Brice, Pauline, Obéric, Lucie, Gaillard, Isabelle, Hunault-Berger, Mathilde, Broussais-Guillaumot, Florence, Gyan, Emmanuel, Bologna, Serge, Nicolas-Virelizier, Emmanuelle, Touati, Mohamed, Casasnovas, Olivier, Delarue, Richard, Orsini-Piocelle, Frédérique, Stamatoullas, Aspasia, Gabarre, Jean, Fornecker, Luc-Matthieu, Gastinne, Thomas, Peyrade, Fréderic, Roland, Virginie, Bachy, Emmanuel, André, Marc, Mounier, Nicolas, Fermé, Christophe

“…Nodular lymphocyte predominant Hodgkin lymphoma represents a distinct entity from classical Hodgkin lymphoma. We conducted a retrospective study to investigate…”
Get full text

PV-0278: Volume concepts in routine radiotherapy for localized Hodgkin lymphoma: results of a national survey by Mazeron, R, Gonzague-Casabianca, L, Peignaux, K, Remouchamps, V, Chira, C, Moisan, P, Lazarovici, J, Edeline, V

Get full text

BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY by Gastinne, T., Bouabdallah, K., Moatti, H., Tessoulin, B., Shiano del colella, J. M., Lamy, T., Casasnovas, O., Borel, C., Stamatoullas, A., Gac, A. C., Chaoui, D., Feugier, P., Delmer, A., Bonnet, C., Fornecker, Luc‐M., Lazarovici, J., Le Bras, F., Ghesquieres, H., Meignan, M., Traverse Glehen, A., Brice, P.

Get full text

Prophylactic Scrotal And Contralateral Testicular Radiation Therapy Prevents Local Relapses in Primary Testicular Lymphomas by Boros, A, Lazarovici, J, Danu, A, Michot, J.M, Gillon, P, Guilhen, M, Felefly, T, Sun, R, Beaudré, A, Arfi-Rouche, J, Bosq, J, Ribrag, V, Mazeron, R

Get full text

OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY by Camus, V., Rossi, C., Sesques, P., Lequesne, J., Tonnelet, D., Haioun, C., Durot, E., Willaume, A., Gauthier, M., Moles‐Moreau, Marie‐P., Antier, C., Lazarovici, J., Monjanel, H., Bernard, S., Tardy, M., Besson, C., Lebras, L., Choquet, S., Le Du, K., Bonnet, C., Bailly, S., Damaj, G.‐L., Laribi, K., Maisonneuve, H., Houot, R., Chauchet, A., Jardin, F., Traverse‐Glehen, A., Decazes, P., Becker, S., Berriolo‐Riedinger, A., Tilly, H.

Get full text

AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS by Marouf, A., Cottereau, A. S., Kanoun, S., Deschamps, P., Franchi, P., Meignan, M., Sibon, D., Gastinne, T., Borel, C., Hammoud, M., Sicard, G., Gille, R., Cavalieri, D., Stamatoullas, A., Clement, L., Lazarovici, J., Chauchet, A., Fornecker, L. M., Amorin, S., Rocquet, M., Raus, N., Burroni, B., Rubio, M. T., Casasnovas, O., Cartron, G., Bouscary, D., Brice, P., Ghesquieres, H., Tamburini, J., Deau, B.

Get full text

OUTCOME AND TREATMENT OF RELAPSING EARLY PET NEGATIVE PATIENTS INCLUDED IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA by Gac, A., Chartier, L., Girinsky, T., Gotti, M., Lazarovici, J., Aurer, I., Musto, P., Damaj, G., Federico, M., Fortpied, C., Raemaekers, J., Meignan, M., Hutchings, M., Versati, A., Andre, M., Reman, O.

Get full text

Use Of 5-Azacitidine for Therapy-Related Myeloid Neoplasms In Patients With Concomitant Active Neoplastic Disease by Annereau, M, Willekens, C, El Halabi, L, Chahine, C, Saada, V, Auger, N, Danu, A, Bermudez, E, Lazarovici, J, Ghez, D, Leary, A, Pistilli, B, Lemare, F, Solary, E, de Botton, S, Desmaris, R.-P, Micol, J.-B

“…Highlights • 30% of patients with t-MDS/AML have a concomitant active neoplastic disorder (CAND). • 5-Azacytidine (AZA) treatment is feasible for t-MDS/AML…”
Get full text

FEASIBILITY AND BENEFIT OF MOLECULARLY‐INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA by Michot, J., Camara‐Clayette, V., Detolle, A., Chahine, C., Lazarovici, J., Danu, A., Bosq, J., Ghez, D., Romano‐Martin, P., Dartigues, P., Arfi‐Rouche, J., Bahleda, R., Rahali, W., Varga, A., Baldini, C., Tselikas, L., Paume, C., Lecourt, H., Cotteret, S., Vergé, V., Soria, J., Massard, C., Ribrag, V.

Get full text

Molecular landscape of relapse/refractory diffuse large B‐cell lymphoma by Michot, J., Camara‐Clayette, V., Chahine, C., Lazarovici, J., Bosq, J., Ghez, D., Dartigues, P., Danu, A., Arfi‐Rouche, J., Tselikas, L., Ba, B., Cotteret, S., Rahali, W., Vergé, V., Ribrag, V.

Get full text

LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY by Delfau‐Larue, M.H., Beldi‐Ferchiou, A., Jais, J., Godard, N., Salles, G.A., Casasnovas, R., Tilly, H., Fruchart, C., Morschhauser, F., Haioun, C., Lazarovici, J., Perrot, A., Sebban, C., Bouabdallah, R., Gonzalez, H., Corront, B., Oberic, L., Briere, J., Gaulard, P., Coiffier, B., Thieblemont, C.

Get full text

Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011) by Demeestere, Isabelle, Racape, Judith, Dechene, Julie, Dupuis, Jehan, Morschhauser, Franck, De Wilde, Virginie, Lazarovici, Julien, Ghesquieres, Hervé, Touati, Mohamed, Sibon, David, Alexis, Magda, Gac, Anne-Claire, Moatti, Hannah, Virelizier, Emmanuelle, Maisonneuve, Hervé, Pranger, Delphine, Houot, Roch, Fornecker, Luc-Matthieu, Tempescul, Adrian, André, Marc, Casasnovas, René-Olivier

“…PURPOSE The prospective, randomized AHL2011 trial demonstrated that the use of the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (ABVD) after…”
Get full text

66P High incidence of TP53 and epigenetic modifying oncogene mutations in a large cohort of patients enrolled in phase I clinical trials for R/R DLBCL by Quivoron, C., Michot, J-M., Camara-Clayette, V., Danu, A., Lazarovici, J., Sarkozy, C., Ghez, D., Rossignol, J., Baldini, C., Martin Romano, P., Varga, A., Cotteret, S., Dartigues, P., Massard, C., Ribrag, V.

Get full text

24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials? by Michot, J-M., Camara-Clayette, V., Quivoron, C., Danu, A., Lazarovici, J., Ghez, D., Rossignol, J., Baldini, C., Martin Romano, P., Sarkozy, C., Varga, A., Cotteret, S., Dartigues, P., Massard, C., Ribrag, V.

Get full text